[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625013":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":29,"collaborators":31,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":23,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":26,"maxAge":43,"enrollmentInfo":44,"targetDuration":26,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":54,"whyStopped":26,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":26},{"fullName":5,"class":6},"NICHD Neonatal Research Network","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous Positive Airway Pressure","EXPERIMENTAL","CPAP will be provided via mask or binasal prongs to maintain a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery whenever available.",[13],"Device: CPAP",{"label":15,"type":16,"description":17,"interventionNames":18},"Nasal Cannula","ACTIVE_COMPARATOR","HFNC at 4 L\u002Fmin will be used initially in the control group. Flow should be titrated down by 1 L\u002Fmin per day until ≤0.5 L\u002Fkg among infants in the nasal cannula group if not meeting pre-specified failure criteria to reduce the risk of inadvertent positive end-expiratory pressure (PEEP). Flow can also be increased (up to 6 L\u002Fmin maximum) if needed among infants on NC who meet the pre-specified failure criteria. Infants in the control group placed back on CPAP may use an interface at provider discretion.",[19],"Device: Nasal Cannula",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","CPAP","Prior to study entry, the CPAP interface (includes RAM cannula, Optiflow, large bore cannulas, mask, prongs) and mode (bubble, variable-flow, ventilator-derived) used is at the discretion of the provider and center. After study entry, CPAP will be provided via mask or binasal prongs to maintain a relatively uniform CPAP delivery system among infants in the treatment group. Bubble CPAP will be preferred over other modes of CPAP delivery whenever available.",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":28,"otherNames":26},[15],{"type":30,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[32],{"name":33,"class":34},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH","100625013","continued-pressure-for-alveolar-protection-cpap-trial-100625013",false,"NCT07417111","Continued Pressure for Alveolar Protection (CPAP Trial)","Continued Pressure for Alveolar Protection: A Randomized Controlled Trial (CPAP Trial)","Inclusion Criteria:\n\n* Gestational age \\\u003C29 weeks at birth\n* PMA \\\u003C32 weeks at study entry\n* On treatment with CPAP without a rate in FiO2 \\\u003C0.25 and PEEP of 4-5 cmH2O\n* Meet stability criteria:\n* If previously intubated must be extubated ≥ 72 hours\n* \\\u003C3 self-resolving apneas (≤ 20 s) and\u002For bradycardia (\\\u003C100 bpm) in any hour over previous 6 hours\n* No episodes of apnea or bradycardia requiring intervention (oxygen\u002Fstimulation\u002Fbag and mask) for 24 hours\n* Parents\u002Flegal guardians consent for enrollment\n\nExclusion Criteria:\n\n* Major malformation\n* Neuromuscular condition that affects respiration\n* Terminal illness\n* Decision to withhold or limit support\n* Too sick to participate in opinion of Attending physician\n* Clinical shock, sepsis\n* Planned surgery during study period","ALL","31 Weeks",{"count":45,"type":46},860,"ESTIMATED","INTERVENTIONAL",[49],"NA","The objective of the CPAP Trial is to test whether extending CPAP until 34 weeks' PMA or for at least 2 additional weeks compared to weaning to a nasal canula will decrease the likelihood of bronchopulmonary dysplasia or death at 36 weeks' PMA.",[52],"Bronchopulmonary Dysplasia (BPD)",[9,23],"NOT_YET_RECRUITING","2026-06-01",{"date":57,"type":58},"2026-06-02","ACTUAL",{"date":60,"type":46},"2026-11-05",{"date":62,"type":46},"2029-01-30",{"name":5,"class":6}]